# A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

> **NCT04132557** · — · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 430000 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** Methylphenidate
- **DRUG:** Lisdexamfetamine
- **DRUG:** Atomoxetine
- **DRUG:** Amphetamine
- **DRUG:** Dextroamphetamine

## Key facts

- **NCT ID:** NCT04132557
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-09
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-10-25
- **Target enrollment:** 430000 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04132557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04132557, "A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04132557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*